OncoCyte Corporation (NASDAQ:OCX) Q1 2025 Earnings Call Transcript
Gabby Woody: Welcome everyone and thank you for joining us to discuss OncoCyte's First Quarter 2025 Results.
Oncocyte Corp (OCX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Broadwood Capital Neal C. Bradsher | 11,410,100 | $34,914,906 | +83% | 2.83% |
| 2. | Pura Vida Investments Efrem Kamen | 947,134 | $2,898,230 | +45% | 21.17% |
| 3. | Citadel Investment Group Ken Griffin | 48,784 | $149,279 | 0% | |
| 4. | Millennium Management Israel Englander | 13,404 | $41,016 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.05 | 97,561 | $200,000.05 | 151,231 | 2025-02-07 | Filing | |
| $2.05 | 1,077,600 | $2,209,080.00 | 2,872,671 | 2025-02-07 | Filing | |
| $0.00 | 0 | $0.00 | 11,410,100 | 2025-02-06 | Filing | |
| $2.05 | 4,505,488 | $9,236,250.40 | 11,410,100 | 2025-02-06 | Filing | |
| $0.00 | 0 | $0.00 | 6,904,612 | 2025-02-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.03 | 40,464 | $41,552.48 | 8,479,682 | 2022-06-24 | Filing | |
| $1.05 | 12,517 | $13,160.37 | 8,520,146 | 2022-06-24 | Filing | |
| $1.03 | 35,441 | $36,394.36 | 7,427,202 | 2022-06-24 | Filing | |
| $1.05 | 10,964 | $11,527.55 | 7,462,643 | 2022-06-24 | Filing | |
| $1.14 | 8,128 | $9,265.92 | 16,872 | 2022-05-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,822,530 | $8,636,942 | 1.19% | |
| 2. | 265,457 | $812,298 | 0% | |
| 3. | 158,907 | $486,331 | 0% | |
| 4. | 79,585 | $243,530 | 0% | |
| 5. | 73,971 | $226,351 | 0.1% |
News See All
OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript
Gabby Woody: Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We also have our analysts with us as panelists.
12 Penny Stocks with Insider Buying in 2025
Insider trading can be a reliable signal for gauging the degree of confidence that management has in the future of their company.
10 Cheapest Stocks Insiders Are Buying Recently
Why should we be interested in affordable stocks? Some investors like to look for cheaper stocks in order to diversify their portfolios, because these penny stocks often operate in different industries...
OncoCyte Corporation (NASDAQ:OCX) Q3 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Kayla, and I will be your conference operator today.
OncoCyte Corporation (NASDAQ:OCX) Q2 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Rochelle, and I will be your conference operator today.
OncoCyte Corporation (NASDAQ:OCX) Q1 2024 Earnings Call Transcript
Operator: Good afternoon. My name is Briana and I will be your conference operator today. At this time, I would like to welcome everyone to the OncoCyte First Quarter 2024 Earnings Conference Call.
OncoCyte Corporation (NASDAQ:OCX) Q3 2023 Earnings Call Transcript
Operator: Thank you for standing by. My name is Tamika and I will be your conference operator today.
OncoCyte Corporation (NASDAQ:OCX) Q2 2023 Earnings Call Transcript
Operator: Welcome to the OncoCyte Q2 2023 Earnings Call. All participants will be in listen-only mode.
OncoCyte Corporation (NASDAQ:OCX) Q1 2023 Earnings Call Transcript
Operator: Good day. And welcome to the OncoCyte First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.
Billionaire Hedge Funds
